評估死海產品作為頭頸癌患者於急性放射化學療法而引起的皮膚和粘膜毒性的預防劑的有效性:一項2期研究

美國國家醫學圖書館 國立衛生研究院   https://www.ncbi.nlm.nih.gov

作者: Isr Med Assoc J. 2007 Jun; 9(6):439-42。

以色列特拉維夫,特拉維夫Sourasky醫學中心腫瘤科Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

 

Assessing the effectiveness of Dead Sea products as prophylactic agents for acute radiochemotherapy-induced skin and mucosal toxicity in patients with head and neck cancers: a phase 2 study.

評估死海產品作為頭頸癌患者於急性放射化學療法而引起的皮膚和粘膜中毒的預防劑的有效性:一項2期研究

 

Abstract

摘要

BACKGROUND:

Mucositis and dermatitis are frequently encountered in patients treated with radiochemotherapy. Dead Sea products that contain minerals and other properties have proven effective in treating various skin diseases.

背景:在放化療治療的患者中經常遇到粘膜炎和皮膚炎。含有礦物質和其他特性的死海產品已被證明可有效治療各種皮膚病。

OBJECTIVES:

To evaluate the effectiveness of Dead Sea products in reducing acute radiochemotherapy-induced side effects in patients with head and neck cancer.

目的:評估死海產品在減輕頭頸癌患者於急性放射化學療法中引起的副作用上的有效性。

METHODS:

In this phase 2 study we compared the outcomes in 24 treated patients and 30 conventionally treated patients matched for age, tumor site, and type of treatment. The Dead Sea products comprised a mouthwash solution (Lenom) and a skin cream (Solaris) used three times daily for 1 week before, during, and up to 2 weeks after completion of radiotherapy. Mucositis and dermatitis were evaluated using common toxicity criteria.

方法:在此2期研究中,我們比較了24例接受治療的患者和30例按年齡,腫瘤部位和治療類型匹配的常規治療患者的結果。死海產品包括漱口液(Lenom)和護膚霜(Solaris),每天三次,分別在放療結束前,放療期間和放療結束後的2週內使用。採用常見的毒性標準評估粘膜炎和皮炎。

RESULTS:

Thirteen treated patients (54%) had grade 1-2 and none had 3-4 mucositis, while 17 controls (57%) had grade 1-2 and 4 (13%) had grade 3-4 mucositis. Thirteen treated patients (54%) had grade 1-2 dermatitis; there was no instance of grade 3-4 dermatitis, while 11 patients in the control group (37%) had grade 1-2 and 5 (17%) had grade 3-4 dermatitis. More patients in the control arm needed a break than did patients in the treatment the control arm needed a break than did patients in the treatment arm (P = 0.034).

結果:13名接受治療的患者(54%)為1-2級,無3-4級粘膜炎,而17名對照者(57%)為1-2級,4名(13%)患有3-4級粘膜炎。 13名接受治療的患者(54%)患有1-2級皮炎;沒有3-4級皮炎的病例,而對照組中的11名患者(37%)為1-2級,而5名患者(17%)為3-4級皮炎。與治療組患者相比,對照組患者需要休息的時間要多於治療組患者(P = 0.034)。

CONCLUSIONS:

The two Dead Sea products tested decreased skin and mucosal toxicity in head and neck cancer patients receiving radiochemotherapy.

結論:測試的兩種死海產品在接受放化療的頭頸癌患者中降低了皮膚和粘膜毒性。

已加入購物車
網路異常,請重新整理